Mark Czekaj

Optimization of the β-Aminoester class of factor Xa inhibitors. part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity

Kevin R. Guertin, Charles J. Gardner, Scott I. Klein et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 52 citations · Full text

Thrombosis, Medicinal Chemistry, Biochemistry +10

Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

Scott I. Klein, Mark Czekaj, Charles J. Gardner et al. · Journal of Medicinal Chemistry · 1998 · 39 citations · Full text

Vitro Potency, Pharmacotherapy, Initial Structure−activity Relationships +20

Design, synthesis, and biological activity of potent and selective inhibitors of mast cell tryptase

Corey R. Hopkins, Mark Czekaj, Steven S. Kaye et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 35 citations · Full text

Biological Activity, Medicinal Chemistry, Allergy +7

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas et al. · The Lancet Diabetes & Endocrinology · 2023 · 34 citations · Full text

Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis

Christopher L. Heran, Suzanne R. Morgan, Charles Kasiewski et al. · European Journal of Pharmacology · 2000 · 32 citations

Thrombosis, Vascular Disease, Cardiovascular Disease +13